Archive August 2009

[TMA]-Pharmacology Watch: Tamoxifen, SSRIs, and Breast Cancer Recurrence

Aug31

Tamoxifen, SSRIs, and Breast Cancer RecurrencePharmacology Watch

[PCR]-Pharmacology Watch

Aug31

Tamoxifen, SSRIs, and Breast Cancer RecurrencePharmacology Watch

[PCR]-Reducing Polypharmacy: Prudent Prescribing in Primary Care

Aug31

Reducing Polypharmacy: Prudent Prescribing in Primary CareAuthors:Dean A. Bricker, MD, Assistant Professor of Medicine, Wright State University, Boonshoft School of Medicine, Dayton, OH; and Anne H. Metzger, PharmD, Assistant Professor of Pharmacy Practice, University of Cincinnati, James L. Winkle College of Pharmacy, Cincinnati, OH.Peer Reviewer:Cynthia Sheppard Solomon, BPharm, RPh, FASCP, President, Sheppard-Solomon Biomedical Consulting, Dayton, […]

[CTU]-New emergency contraception options are here, but how are you to use them?

Aug31

New emergency contraception options are here, but how are you to use them?FDA approves Plan B One-Step and Next ChoiceGetting ready to advise your next patient about the importance of emergency contraception (EC)? Be prepared to discuss two new emergency contraceptive products, just approved by the Food and Drug Administration (FDA): ?Plan B One-Step (levonorgestrel […]

[CRC]-Pharmacology Watch: Tamoxifen, SSRIs, and Breast Cancer Recurrence

Aug31

Tamoxifen, SSRIs, and Breast Cancer RecurrencePharmacology Watch

[IDA]-Pharmacology Watch: Tamoxifen, SSRIs, and Breast Cancer Recurrence

Aug31

Tamoxifen, SSRIs, and Breast Cancer RecurrencePharmacology Watch

[COA]-Pharmacology Watch

Aug31

Tamoxifen, SSRIs, and Breast Cancer RecurrencePharmacology Watch

[SHW]-Fiscal Fitness: How States Cope: New Mexico Medicaid has some difficult choices to make for FY 2010

Aug31

Fiscal Fitness: How States CopeNew Mexico Medicaid has some difficult choices to make for FY 2010A long list of proposed cost- containment possibilities for New Mexico’s Medicaid program never happened, due to funding the state received from the American Recovery and Reinvestment Act (ARRA) of 2009. Other than tightening up its managed care contracts, no […]

[CCA]-Pharmacology Watch

Aug31

Tamoxifen, SSRIs, and Breast Cancer RecurrencePharmacology Watch

Research and Markets: Emerging Opportunities in Controlled-Release Generic Drugs: New Report Identifies 30 Controlled-Release Drugs Valued at US$15 Billion

Aug31

DUBLIN(BUSINESS WIRE) Research and Markets has announced the addition of the "Emerging Opportunities in Controlled-Release Generic Drugs" report to their offering. This new report identifies 30 controlled-release drugs valued at US$15 billion, many of which will be losing patent protection in the medium term. From emerging specialist companies to established generic producers, alternative drug delivery […]